Associate Director, Intellectual Property
Revolution Medicines
Summary
We are seeking a trademark and copyright attorney to join our IP team. In this newly created role, you will share responsibility for RevMed's expanding global trademarks and domains practice, spanning clearance, prosecution, portfolio management, and enforcement.
Job description
The Opportunity
We are seeking a trademark and copyright attorney to join our IP team. In this newly created role, you will share responsibility for RevMed's expanding global trademarks and domains practice, spanning clearance, prosecution, portfolio management, and enforcement.
- Execute global trademark strategy; determine trademark filing, prosecution and portfolio maintenance priorities in alignment with commercial objectives, and direct outside counsel to implement those decisions.
Requirements
- 6-10 years of relevant legal experience at a law firm and/or in an in-house role
- J.D. degree from an ABA accredited law school
- Member in good standing of the California Bar, or eligible for in-house registration in California
- Admitted to practice before the U.S. Patent and Trademark Office
- Demonstrable experience in global trademark portfolio management and enforcement
- Strong organizational and time-management skills
- Ability to prioritize and manage multiple time-sensitive projects simultaneously
- Ability to multi-task, prioritize options, anticipate challenges and execute on goals as a member of an interdisciplinary team
- Collaborative, flexible, positive and pragmatic work style
- Excellent written and verbal communication skills
- Ability to simplify the complex and adapt to audiences with varying levels of legal fluency
- Flexibility, adaptability, and willingness to contribute beyond core responsibilities
Benefits
- Equity Awards
- Learning & Development
- Competitive Cash Compensation
- Strong Benefits
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.